Evidence map›Paper›PMID 37010102›Full record

ArticleHuman molecular genetics2023

Pathogenic SCN2A variants cause early-stage dysfunction in patient-derived neurons.

R Asadollahi, I Delvendahl, R Muff, G Tan, D G Rodríguez, S Turan, M Russo, B Oneda, P Joset, P Boonsawat and 14 more

Open access · hybridAbstract read
In one paragraph

Article in Human molecular genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 29 citations in OpenAlex.

  1. Genetic Diagnosis in Epilepsy: Implications for Clinical Management.Current neurology and neuroscience reports · 2026
    Review
  2. Excitatory Dysfunction and Phenotypic Rescue in a Human Neuronal Model ofbioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Neurologist's Black Swan: Molecular Basis of Prenatal Seizures.International journal of molecular sciences · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Distinctive In Vitro Phenotypes in iPSC-Derived Neurons From Patients With Gain- and Loss-of-FunctionThe Journal of neuroscience : the official journal of the Society for Neuroscience · 2024
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 4 institutions in 3 countries.

R AsadollahiInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
I DelvendahlDepartment of Molecular Life Sciences, University of Zurich, Zurich 8057, Switzerland.
R MuffInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
G TanFunctional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
D G RodríguezFunctional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
S TuranDepartment of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
M RussoInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
B OnedaInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
P JosetInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
P BoonsawatInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
R MasoodInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
M MoceraInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
I IvanovskiInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
A BaumerInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
R Bachmann-GagescuInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
R SchlapbachFunctional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
H RehrauerFunctional Genomics Center Zurich, ETH Zurich and University of Zurich, Zurich 8057, Switzerland.
K SteindlInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
A BegemannInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
A ReisInstitute of Human Genetics, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
J WinklerDepartment of Molecular Neurology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
B WinnerDepartment of Stem Cell Biology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen 91054, Germany.
M MüllerDepartment of Molecular Life Sciences, University of Zurich, Zurich 8057, Switzerland.
A RauchInstitute of Medical Genetics, University of Zurich, Schlieren-Zurich 8952, Switzerland.
University of Zurich · CHFriedrich-Alexander-Universität Erlangen-Nürnberg · DEETH Zurich · CHSwiss Integrative Center for Human Health · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenic heterozygous variants in SCN2A, which encodes the neuronal sodium channel NaV1.2, cause different types of epilepsy or intellectual disability (ID)/autism without seizures. Previous studies using mouse models or heterologous systems suggest that NaV1.2 channel gain-of-function typically causes epilepsy, whereas loss-of-function leads to ID/autism. How altered channel biophysics translate into patient neurons remains unknown. Here, we investigated iPSC-derived early-stage cortical neurons from ID patients harboring diverse pathogenic SCN2A variants [p.(Leu611Valfs*35); p.(Arg937Cys); p.(Trp1716*)] and compared them with neurons from an epileptic encephalopathy (EE) patient [p.(Glu1803Gly)] and controls. ID neurons consistently expressed lower NaV1.2 protein levels. In neurons with the frameshift variant, NaV1.2 mRNA and protein levels were reduced by ~ 50%, suggesting nonsense-mediated decay and haploinsufficiency. In other ID neurons, only protein levels were reduced implying NaV1.2 instability. Electrophysiological analysis revealed decreased sodium current density and impaired action potential (AP) firing in ID neurons, consistent with reduced NaV1.2 levels. In contrast, epilepsy neurons displayed no change in NaV1.2 levels or sodium current density, but impaired sodium channel inactivation. Single-cell transcriptomics identified dysregulation of distinct molecular pathways including inhibition of oxidative phosphorylation in neurons with SCN2A haploinsufficiency and activation of calcium signaling and neurotransmission in epilepsy neurons. Together, our patient iPSC-derived neurons reveal characteristic sodium channel dysfunction consistent with biophysical changes previously observed in heterologous systems. Additionally, our model links the channel dysfunction in ID to reduced NaV1.2 levels and uncovers impaired AP firing in early-stage neurons. The altered molecular pathways may reflect a homeostatic response to NaV1.2 dysfunction and can guide further investigations.

Indexed as

EpilepsyIntellectual DisabilityHumansNAV1.2 Voltage-Gated Sodium ChannelNeuronsSeizuresSodiumSodium ChannelsNAV1.2 Voltage-Gated Sodium ChannelSodiumSodium Channels

Identifiers

PMID37010102
PMCPMC10281746
OpenAlexW4362506132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.